Fintel reports that on May 19, 2026, Citigroup initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Neutral recommendation.
Analyst Price Forecast Suggests 59.71% Upside
As of May 14, 2026, the average one-year price target for BridgeBio Pharma is $105.41/share. The forecasts range from a low of $80.80 to a high of $164.85. The average price target represents an increase of 59.71% from its latest reported closing price of $66.00 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BridgeBio Pharma is 586MM, an increase of 1.09%. The projected annual non-GAAP EPS is -3.15.
What is the Fund Sentiment?
There are 475 funds or institutions reporting positions in BridgeBio Pharma. This is an decrease of 240 owner(s) or 33.57% in the last quarter. Average portfolio weight of all funds dedicated to BBIO is 0.40%, an increase of 0.29%. Total shares owned by institutions increased in the last three months by 0.26% to 213,444K shares. 
The put/call ratio of BBIO is 1.15, indicating a bearish outlook.
What are Other Shareholders Doing?
Kohlberg Kravis Roberts & Co. holds 13,261K shares representing 6.77% ownership of the company. No change in the last quarter.
Janus Henderson Group holds 13,179K shares representing 6.73% ownership of the company. In its prior filing, the firm reported owning 11,000K shares , representing an increase of 16.53%. The firm decreased its portfolio allocation in BBIO by 56.21% over the last quarter.
Viking Global Investors holds 11,842K shares representing 6.05% ownership of the company. In its prior filing, the firm reported owning 14,394K shares , representing a decrease of 21.55%. The firm decreased its portfolio allocation in BBIO by 15.81% over the last quarter.
Farallon Capital Management holds 9,365K shares representing 4.78% ownership of the company. In its prior filing, the firm reported owning 8,998K shares , representing an increase of 3.92%. The firm increased its portfolio allocation in BBIO by 22.06% over the last quarter.
Vanguard Portfolio Management holds 8,081K shares representing 4.13% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
